American Drug War 2: Cannabis destiny (2013)
Director Kevin Booth navigates through the cutting edge of Cannabis research while becoming a foster parent to a child court ordered to take powerful mind altering drugs From the frontlines…
Tags: GW Pharmaceuticals
FDA Grants Fast Track Designation of Cannabis Drug to Treat Newborns
6 August 2015: GW Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal…
Three Studies Shed New Light on the Effectiveness of Cannabis in Epilepsy
West Hartford, Conn., October 14, 2014 In advance of the American Epilepsy Societys (AES) Annual Meeting in December, the organization has offered highlights of groundbreaking research being studied at…
GW Pharmaceuticals Epidiolex® Orphan Designation from European Medicines Agency and Fast Track Designation
Cannabis Based Drug Epidiolex® Receives Orphan Designation from European Medicines Agency and Fast Track designation from the FDA for the Treatment of Dravet Syndrome London, UK; 22 October 2014: GW…
GW Pharmaceuticals Announces New Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy
14 October 2014: GW Pharmaceuticals plc announced new physician reports of efficacy and safety associated with the Epidiolex® “expanded access” studies. Physician reports of efficacy and safety data have been…
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Ulcerative Colitis Trial
14 October 2014: The Phase 2a pilot trial was a 10-week randomized, double-blind, placebo controlled study of GWP42003 extract, which features Cannabidiol (CBD) as the primary cannabinoid and which also…
Cannabis drug Epidiolex reduces seizures by 50% and stops them completely in some cases
London, UK; 17 June 2014: GW Pharmaceuticals a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced physician reports of efficacy…
Epidiolex, A Cannabis Medicine Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome
London, UK; 6 June 2014: GW Pharmaceuticals a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States…
Georgia State Forms Partnership With GW Pharmaceutical for CBD Trials
27 May 2014 – The state, GW Pharmaceuticals (NASDAQ: GWPH), and Georgia Regents University Augusta (GRU), announced today that they have entered into a Memorandum of Understanding to study GW’s…
Free Neil Morgan – A Strange Justice That Convicts For Victimless Private Activities
It is disturbing to see Court cases where there are no victims and the only losers are the defendant and the taxpayers and one should be forgiven for thinking such…
